Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,605 matching trials from the live ClinicalTrials.gov search.
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Conditions
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome
Interventions
MPH966
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gastrointestinal Adenocarcinomas
Interventions
MEDI-565
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Durham, North Carolina + 1 more
Conditions
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
Interventions
Vincristine, Prednisone, Doxorubicin, Etoposide, Pomalidomide, Cyclophosphamide, Rituximab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin

NCT02630303
Conditions
Fibrosis, Scarring, Scar, Wounds, Injuries, Keloid, Cicatrix, Hypertrophic
Interventions
LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
Jared Jagdeo, MD, MS
Federal
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mather, California
Conditions
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions
TNG348, Olaparib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more
Conditions
Pulmonary Arterial Hypertension
Interventions
APD811, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
Conditions
Refractory Brain Tumors
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukaemia, Myelocytic, Acute
Interventions
GSK2879552, ATRA
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Augusta, Georgia • New York, New York • The Bronx, New York + 1 more
Conditions
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
tanespimycin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carbendazim
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Erlotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
Orange, California • New Haven, Connecticut • Orlando, Florida + 5 more
Conditions
Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma
Interventions
Zotiraciclib (TG02), Temozolomide (TMZ)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced/Metastatic Tumors
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more
Conditions
Advanced Solid Tumor
Interventions
XTX301
Drug
Lead sponsor
Xilio Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
Interventions
Afatinib, Pemigatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
Interventions
DKN-01
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Scottsdale, Arizona • Albany, New York • Greenville, South Carolina + 5 more
Conditions
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Interventions
Vemurafenib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 15 more
Conditions
Pancreatic Cancer, Cancer
Interventions
Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine, Gemcitabine + Erlotinib, Gemcitabine, Photon
Radiation · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Advanced Cancer
Interventions
JNJ-61610588
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin's
Interventions
cemsidomide, Dexamethasone Oral
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Conditions
Leukemia, Myeloid, Acute
Interventions
BAY1436032
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Buffalo, New York • New York, New York • The Bronx, New York + 4 more
Conditions
Lung Cancer
Interventions
carboplatin, nab-paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Paducah, Kentucky • Portland, Oregon • Chattanooga, Tennessee + 1 more
Conditions
Solid Tumor, MET Alteration
Interventions
VERT-002
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee